Vitalii Yu. Roshchin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vitalii Yu. Roshchin has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Denis Y. Kachanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
17 shared publications В. Ю. Рощин
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева» Минздрава России
15 shared publications- Tatyana V. Shamanskaya
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of the Russian Federation
13 shared publications - Alexander E. Druy
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
10 shared publications - Galina V. Tereshchenko
Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
10 shared publications - Dmitry M. Konovalov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
9 shared publications
Latest Publications
- Open Access
- 14 January 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (4) , 11-26
Hepatocellular carcinoma in children and adolescents: results of a retrospective analysis
Hepatocellular carcinoma (HCC) is a rare primary liver malignancy in children and adolescents with poor prognosis. The aim of the study – to evaluate the clinical characteristics, treatment strategies, and outcomes in pediatric and adolescent patients with HCC, and to identify factors influencing survival. Materials and methods . A retrospective analysis was conducted on 39 patients aged 4 to 16 years with histologically confirmed HCC treated and consulted at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between 2012 and 2023. Demographic and clinical features, underlying predisposing conditions, laboratory findings, intrahepatic tumor spread (PRETEXT staging), surgical interventions, and systemic treatment regimens were analyzed. Results. Median age was 133.5 months (11.1 years; range 49.7–199.4 months). Male to female ratio was 1.1:1. HCC developed de novo in 77 % of patients, while 23 % had predisposing conditions – most commonly chronic hepatitis B. The clinical presentation was predominantly non-specific, and in 28.9 % of cases, the tumor was discovered incidentally. Serum alpha-fetoprotein levels were within normal limits in 45% of patients, particularly in those with fibrolamellar HCC. Advanced intrahepatic tumor spread (PRETEXT stage III–IV) was observed in 60 % of cases, and distant metastases were present in 18 % of patients. The 5-year overall survival (OS) was 37 %, and the event-free survival was 26 %. The presence of distant metastases was significantly associated with inferior outcomes (5-year OS: 45 % in non-metastatic vs. 0 % in metastatic cases, p < 0.001). PRETEXT stage and histological subtype showed no significant impact on OS or event-free survival. Surgical treatment (hepatic resection or orthotopic liver transplantation) was performed in 66 % of patients and was significantly associated with improved outcomes: 5-year OS was 54 % in the surgical group versus 0 % in those who did not undergo surgery (p < 0.001). Liver transplantation showed a trend toward better outcomes compared to resection, although the difference was not statistically significant. Initial treatment strategy (primary resection vs. biopsy with neoadjuvant chemotherapy) had no impact on survival. Conclusion s. Pediatric HCC is a rare but highly aggressive malignancy that is often diagnosed at an advanced stage. Radical surgical resection, including liver transplantation in certain cases, remains the primary determinant of prognosis. Improved outcomes require early diagnosis, early discussion of therapeutic tactics in center specialized in hepatobiliary surgery and inclusion of pediatric patients in multicenter clinical trials.
- 14 January 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (4) , 11-26
Open AccessHepatocellular carcinoma in children and adolescents: results of a retrospective analysis
Hepatocellular carcinoma (HCC) is a rare primary liver malignancy in children and adolescents with poor prognosis. The aim of the study – to evaluate the clinical characteristics, treatment strategies, and outcomes in pediatric and adolescent patients with HCC, and to identify factors influencing survival. Materials and methods . A retrospective analysis was conducted on 39 patients aged 4 to 16 years with histologically confirmed HCC treated and consulted at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between 2012 and 2023. Demographic and clinical features, underlying predisposing conditions, laboratory findings, intrahepatic tumor spread (PRETEXT staging), surgical interventions, and systemic treatment regimens were analyzed. Results. Median age was 133.5 months (11.1 years; range 49.7–199.4 months). Male to female ratio was 1.1:1. HCC developed de novo in 77 % of patients, while 23 % had predisposing conditions – most commonly chronic hepatitis B. The clinical presentation was predominantly non-specific, and in 28.9 % of cases, the tumor was discovered incidentally. Serum alpha-fetoprotein levels were within normal limits in 45% of patients, particularly in those with fibrolamellar HCC. Advanced intrahepatic tumor spread (PRETEXT stage III–IV) was observed in 60 % of cases, and distant metastases were present in 18 % of patients. The 5-year overall survival (OS) was 37 %, and the event-free survival was 26 %. The presence of distant metastases was significantly associated with inferior outcomes (5-year OS: 45 % in non-metastatic vs. 0 % in metastatic cases, p < 0.001). PRETEXT stage and histological subtype showed no significant impact on OS or event-free survival. Surgical treatment (hepatic resection or orthotopic liver transplantation) was performed in 66 % of patients and was significantly associated with improved outcomes: 5-year OS was 54 % in the surgical group versus 0 % in those who did not undergo surgery (p < 0.001). Liver transplantation showed a trend toward better outcomes compared to resection, although the difference was not statistically significant. Initial treatment strategy (primary resection vs. biopsy with neoadjuvant chemotherapy) had no impact on survival. Conclusion s. Pediatric HCC is a rare but highly aggressive malignancy that is often diagnosed at an advanced stage. Radical surgical resection, including liver transplantation in certain cases, remains the primary determinant of prognosis. Improved outcomes require early diagnosis, early discussion of therapeutic tactics in center specialized in hepatobiliary surgery and inclusion of pediatric patients in multicenter clinical trials.
- Open Access
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 22-38
Results of treatment of patients with posterior mediastinal neuroblastoma in the observation group
Background . Neuroblastoma (NB) with primary tumor located in the posterior mediastinum is a unique subgroup characterized by a higher incidence of life-threatening complications, such as epidural compression (EC) and respiratory failure, yet it is associated with favorable long-term outcomes. Materials and methods . The study included patients with low-risk posterior mediastinal NB treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between January 2012 and September 2024 (152 months). Patients were stratified into risk groups and managed according to the GPOH-NB2004 protocol. We evaluated relapse/progression detection methods, disease characteristics, treatment approaches, and long-term outcomes. Results . The study included 146 patients with NB with primary tumor located in the posterior mediastinum, which is 21.6 % of all patients in the observation (low-risk) group registered in the research database of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The median age at diagnosis was 19.6 months (range 0.5–132.5 months) with a female predominance (male-to-female ratio 1:1.2). Most patients (85/146; 58.2 %) presented with stage 2 disease. 38/146 (26.0 %) patients received chemotherapy due to life threatening symptoms, primarily EC, while 87/146 (59.6 %) patients underwent best surgery in the volume of a macroscopic residual tumor. Relapse/progression occurred in 16.4 % (24/146), predominantly detected during routine follow-up imaging (18/24; 75,0 %), with a median time to relapse of 7.8 months (range 3.0–25.3 months). The majority of relapses/progressions were local (18/24; 75.0 %). In 93 % (14/15) of relapsed/progressed cases analyzed retrospectively, MLPA revealed segmental chromosomal aberrations (median 3 aberrations/ patient; range 0–6). The most frequent alterations included 17q gain (n = 11), 2p gain (n = 8), and deletions in 3p (n = 6), 11q (n = 5), and 4q (n = 4). The 5-year event-free survival in patients with mediastinal NB was 79,1 ± 4,0 %, patients with stage 1 showing the highest survival rates (90 ± 6 %) (p = 0.1932). The 5-year overall survival was 95,0 ± 2,1 %. The cumulative incidence of relapse/progression was 18.7 ± 3.5 %, while treatment-related mortality was 2.8 ± 1.4 % (one death from disease progression; five from therapy toxicity). Conclusions. Mediastinal NB is a prognostically favorable group, with excellent survival rates independent of age or stage. Most patients in the low-risk group achieved favorable outcomes, even after relapse/progression. For the majority of patients in the low-risk group, surgery only is sufficient, and this strategy allows to reduce the risk of mortality from the toxicity of therapy without reducing overall survival. However, chemotherapy remains critical for patients with life-threatening complications, such as EC and respiratory failure, which once again highlighting the challenges in managing this subgroup. Strict adherence to the entire follow-up plan during the period of catamnesis is essential for early relapse detection. The molecular profile of the tumor may predict relapses and treatment response, which underscores the need to integrate molecular diagnostic methods (MLPA) to all patients with NB in the low-risk group into routine diagnostics.
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 22-38
Open AccessResults of treatment of patients with posterior mediastinal neuroblastoma in the observation group
Background . Neuroblastoma (NB) with primary tumor located in the posterior mediastinum is a unique subgroup characterized by a higher incidence of life-threatening complications, such as epidural compression (EC) and respiratory failure, yet it is associated with favorable long-term outcomes. Materials and methods . The study included patients with low-risk posterior mediastinal NB treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between January 2012 and September 2024 (152 months). Patients were stratified into risk groups and managed according to the GPOH-NB2004 protocol. We evaluated relapse/progression detection methods, disease characteristics, treatment approaches, and long-term outcomes. Results . The study included 146 patients with NB with primary tumor located in the posterior mediastinum, which is 21.6 % of all patients in the observation (low-risk) group registered in the research database of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The median age at diagnosis was 19.6 months (range 0.5–132.5 months) with a female predominance (male-to-female ratio 1:1.2). Most patients (85/146; 58.2 %) presented with stage 2 disease. 38/146 (26.0 %) patients received chemotherapy due to life threatening symptoms, primarily EC, while 87/146 (59.6 %) patients underwent best surgery in the volume of a macroscopic residual tumor. Relapse/progression occurred in 16.4 % (24/146), predominantly detected during routine follow-up imaging (18/24; 75,0 %), with a median time to relapse of 7.8 months (range 3.0–25.3 months). The majority of relapses/progressions were local (18/24; 75.0 %). In 93 % (14/15) of relapsed/progressed cases analyzed retrospectively, MLPA revealed segmental chromosomal aberrations (median 3 aberrations/ patient; range 0–6). The most frequent alterations included 17q gain (n = 11), 2p gain (n = 8), and deletions in 3p (n = 6), 11q (n = 5), and 4q (n = 4). The 5-year event-free survival in patients with mediastinal NB was 79,1 ± 4,0 %, patients with stage 1 showing the highest survival rates (90 ± 6 %) (p = 0.1932). The 5-year overall survival was 95,0 ± 2,1 %. The cumulative incidence of relapse/progression was 18.7 ± 3.5 %, while treatment-related mortality was 2.8 ± 1.4 % (one death from disease progression; five from therapy toxicity). Conclusions. Mediastinal NB is a prognostically favorable group, with excellent survival rates independent of age or stage. Most patients in the low-risk group achieved favorable outcomes, even after relapse/progression. For the majority of patients in the low-risk group, surgery only is sufficient, and this strategy allows to reduce the risk of mortality from the toxicity of therapy without reducing overall survival. However, chemotherapy remains critical for patients with life-threatening complications, such as EC and respiratory failure, which once again highlighting the challenges in managing this subgroup. Strict adherence to the entire follow-up plan during the period of catamnesis is essential for early relapse detection. The molecular profile of the tumor may predict relapses and treatment response, which underscores the need to integrate molecular diagnostic methods (MLPA) to all patients with NB in the low-risk group into routine diagnostics.
- Open Access
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 103-112
RET-rearranged spindle cell soft tissue sarcoma in children: description of a clinical case and literature review
Soft tissue sarcomas (SMTs) represent a heterogeneous group of malignant tumors of mesenchymal origin. The widespread introduction of next-generation sequencing techniques, including RNA sequencing, into clinical practice has led to the description of a variety of SMTs with rearrangements of genes encoding various kinases. The present article describes the clinical case of a 3-year-old patient with a low-grade spindle cell sarcoma with a detectable MYH10::RET RNA transcript. The literature review describes the role of the RET gene in the pathogenesis of malignant neoplasms, with emphasis on soft tissue tumors, and presents the clinical, molecular and genetic characteristics of pediatric cases of SMT with RET gene rearrangements and the results of their therapy. The role of various molecular oncology techniques in the identification of kinase gene rearrangements, including RET, is discussed.
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 103-112
Open AccessRET-rearranged spindle cell soft tissue sarcoma in children: description of a clinical case and literature review
Soft tissue sarcomas (SMTs) represent a heterogeneous group of malignant tumors of mesenchymal origin. The widespread introduction of next-generation sequencing techniques, including RNA sequencing, into clinical practice has led to the description of a variety of SMTs with rearrangements of genes encoding various kinases. The present article describes the clinical case of a 3-year-old patient with a low-grade spindle cell sarcoma with a detectable MYH10::RET RNA transcript. The literature review describes the role of the RET gene in the pathogenesis of malignant neoplasms, with emphasis on soft tissue tumors, and presents the clinical, molecular and genetic characteristics of pediatric cases of SMT with RET gene rearrangements and the results of their therapy. The role of various molecular oncology techniques in the identification of kinase gene rearrangements, including RET, is discussed.
- 10 December 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (6)
Modern treatment approaches for advanced hepatocellular carcinoma in children: a clinical case report and a bibliographical review
Hepatocellular carcinoma (HCC) is a rare primary malignant tumor of the liver in childhood accounting for 20% to 33% of cases. Important prognostic factors are the presence of distant metastases and tumor unresectability. Currently there are no proven curative treatment options for pediatric patients with the abovementioned unfavorable prognostic factors. Authors represent a clinical case report of the HCC development with intra-abdominal metastases in an 8 years old pediatric patient. The Lenvatinib therapy with previous cytostatic therapy combined with sorafenib allowed the 6 months control over the tumor process whilst maintaining reasonably good quality of life of a patient.
- 10 December 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (6)
Modern treatment approaches for advanced hepatocellular carcinoma in children: a clinical case report and a bibliographical review
Hepatocellular carcinoma (HCC) is a rare primary malignant tumor of the liver in childhood accounting for 20% to 33% of cases. Important prognostic factors are the presence of distant metastases and tumor unresectability. Currently there are no proven curative treatment options for pediatric patients with the abovementioned unfavorable prognostic factors. Authors represent a clinical case report of the HCC development with intra-abdominal metastases in an 8 years old pediatric patient. The Lenvatinib therapy with previous cytostatic therapy combined with sorafenib allowed the 6 months control over the tumor process whilst maintaining reasonably good quality of life of a patient.
- Open Access
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 158-163
Fibrocartilaginous mesenchymoma: a case report and a literature review
Fibrocartilaginous mesenchymoma of the bone is an extremely rare, locally aggressive tumor which is most often found in the long bones of younger patients. Only about 36 cases have been described in the world literature since 1984. Here, we report a rare clinical case of fibrocartilaginous mesenchymoma of the bone in a 13-year-old child. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 158-163
Open AccessFibrocartilaginous mesenchymoma: a case report and a literature review
Fibrocartilaginous mesenchymoma of the bone is an extremely rare, locally aggressive tumor which is most often found in the long bones of younger patients. Only about 36 cases have been described in the world literature since 1984. Here, we report a rare clinical case of fibrocartilaginous mesenchymoma of the bone in a 13-year-old child. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
- Open Access
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 134-143
Congenital chest wall spindle cell rhabdomyosarcoma in a one-month-old patient
This article presents a rare clinical case of an infant with congenital spindle-cell rhabdomyosarcoma, demonstrates a combined approach to the patient's therapy, describes in detail the performed reconstructive plastic surgery, analyzes the short-term and long-term results of the treatment with an emphasis on late orthopedic complications, provides a detailed literary review on the topic of the publication. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 134-143
Open AccessCongenital chest wall spindle cell rhabdomyosarcoma in a one-month-old patient
This article presents a rare clinical case of an infant with congenital spindle-cell rhabdomyosarcoma, demonstrates a combined approach to the patient's therapy, describes in detail the performed reconstructive plastic surgery, analyzes the short-term and long-term results of the treatment with an emphasis on late orthopedic complications, provides a detailed literary review on the topic of the publication. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
- Open Access
- 15 September 2023
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 15 (3) , 52-57
Adamantinoma in a 4-year-old child (clinical case)
The article describes a clinical case of development of a rare malignant tumor adamantinoma in a 4-year-old child, difficulties in its diagnosis, and tactics of surgical treatment. Literature data on epidemiology, differential diagnosis, and treatment methods for this pathology, as well as statistical data on local and metastatic recurrences, are presented. Recommendations on dynamic observation of patients with adamantinoma are given.
- 15 September 2023
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 15 (3) , 52-57
Open AccessAdamantinoma in a 4-year-old child (clinical case)
The article describes a clinical case of development of a rare malignant tumor adamantinoma in a 4-year-old child, difficulties in its diagnosis, and tactics of surgical treatment. Literature data on epidemiology, differential diagnosis, and treatment methods for this pathology, as well as statistical data on local and metastatic recurrences, are presented. Recommendations on dynamic observation of patients with adamantinoma are given.
- Open Access
- 12 May 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (2) , 65-91
The results of therapy in patients with high-risk neuroblastoma: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
Treatment of patients with high-risk neuroblastoma (NB) is a complex challenge, and it is based on response to certain elements of therapy. The development and introduction of new treatment approaches, such as GD2-targeted immunotherapy (IT), leads to improved survival in this cohort of patients. The aim of the study was to retrospectively assess the effectiveness of therapy in patients with high-risk NB before the introduction of IT into clinical practice. We retrospectively analyzed the data of 151 NB patients stratified into a high-risk group who had received treatment in accordance with the modified NB2004 protocol of the German Society for Pediatric Oncology and Hematology (GPOH) at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from 01.2012 to 12.2017. This study was approved by the Independent Ethics Committee and the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. All the study subjects (or their legal representatives) signed a voluntary informed consent form indicating their agreement to treatment and use of their data for research purposes. Overall survival (OS), event-free survival (EFS), and risk factors were analyzed in the patients with high-risk NB including those who had completed multimodal therapy with autologous hematopoietic stem cell transplantation and post-consolidation therapy with isotretinoin and had achieved a satisfactory response to induction therapy (complete response (CR), very good partial response (VGPR), partial response (PR)) (population of special interest). The main unfavorable prognostic clinical and molecular genetic factors affecting survival in the high-risk NB patients were older age, MYCN gene amplification, and stage 4 of the disease. The use of the modified GPOH NB2004 protocol resulted in a satisfactory response (CR/VGPR/PR) to the induction therapy in most patients: 124/151 (82.1 %). Surgery (other than primary tumor biopsy) led to improved survival, with no statistical difference between macroscopic radical surgery and macroscopic residual tumor. At the same time, radiation therapy (RT), as the second element of local control, had a significant impact on EFS in the group of the patients with stage 4 disease: the 3-year EFS was 39.4 % (95 % confidence interval (CI) 23.1–55.4) in the patients with RT versus 25.7 % (95 % CI 17.5–34.7) in the patients without RT (p = 0.0295). The introduction of a new high-dose TreoMel chemotherapy regimen did not result in worse survival rates but led to a decrease in transplant-related toxicity. The 5-year OS and 5-year EFS were 49.4 % (95 % CI 40.9–57.3 %) and 33.3 % (95 % CI 25.9–40.9) respectively for all the study subjects, and 81.6 % (95 % CI 70.3–88.9) and 55.1 % (95 % CI 43.1–65.5) respectively for the patients from the population of special interest. The analysis of the results of therapy in the high-risk NB patients who had received treatment at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, yielded results comparable to those of the original GPOH NB2004 protocol. The patients with CR/VGPR/PR to the induction therapy who had completed the protocol treatment with autologous hematopoietic stem cell transplantation and isotretinoin post-consolidation therapy demonstrated higher 5-year EFS rates. However, there remains a need to develop more effective treatment regimens for high-risk NB.
- 12 May 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (2) , 65-91
Open AccessThe results of therapy in patients with high-risk neuroblastoma: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
Treatment of patients with high-risk neuroblastoma (NB) is a complex challenge, and it is based on response to certain elements of therapy. The development and introduction of new treatment approaches, such as GD2-targeted immunotherapy (IT), leads to improved survival in this cohort of patients. The aim of the study was to retrospectively assess the effectiveness of therapy in patients with high-risk NB before the introduction of IT into clinical practice. We retrospectively analyzed the data of 151 NB patients stratified into a high-risk group who had received treatment in accordance with the modified NB2004 protocol of the German Society for Pediatric Oncology and Hematology (GPOH) at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from 01.2012 to 12.2017. This study was approved by the Independent Ethics Committee and the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. All the study subjects (or their legal representatives) signed a voluntary informed consent form indicating their agreement to treatment and use of their data for research purposes. Overall survival (OS), event-free survival (EFS), and risk factors were analyzed in the patients with high-risk NB including those who had completed multimodal therapy with autologous hematopoietic stem cell transplantation and post-consolidation therapy with isotretinoin and had achieved a satisfactory response to induction therapy (complete response (CR), very good partial response (VGPR), partial response (PR)) (population of special interest). The main unfavorable prognostic clinical and molecular genetic factors affecting survival in the high-risk NB patients were older age, MYCN gene amplification, and stage 4 of the disease. The use of the modified GPOH NB2004 protocol resulted in a satisfactory response (CR/VGPR/PR) to the induction therapy in most patients: 124/151 (82.1 %). Surgery (other than primary tumor biopsy) led to improved survival, with no statistical difference between macroscopic radical surgery and macroscopic residual tumor. At the same time, radiation therapy (RT), as the second element of local control, had a significant impact on EFS in the group of the patients with stage 4 disease: the 3-year EFS was 39.4 % (95 % confidence interval (CI) 23.1–55.4) in the patients with RT versus 25.7 % (95 % CI 17.5–34.7) in the patients without RT (p = 0.0295). The introduction of a new high-dose TreoMel chemotherapy regimen did not result in worse survival rates but led to a decrease in transplant-related toxicity. The 5-year OS and 5-year EFS were 49.4 % (95 % CI 40.9–57.3 %) and 33.3 % (95 % CI 25.9–40.9) respectively for all the study subjects, and 81.6 % (95 % CI 70.3–88.9) and 55.1 % (95 % CI 43.1–65.5) respectively for the patients from the population of special interest. The analysis of the results of therapy in the high-risk NB patients who had received treatment at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, yielded results comparable to those of the original GPOH NB2004 protocol. The patients with CR/VGPR/PR to the induction therapy who had completed the protocol treatment with autologous hematopoietic stem cell transplantation and isotretinoin post-consolidation therapy demonstrated higher 5-year EFS rates. However, there remains a need to develop more effective treatment regimens for high-risk NB.
- Open Access
- 29 June 2022
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 8 (5)
Case report: EWSR1-TFCP2 in an adolescent represents an extremely rare and aggressive form of intraosseous spindle cell rhabdomyosarcomas
The World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone subdivides rhabdomyosarcomas (RMSs) into alveolar, embryonal, pleomorphic, and spindle cell RMSs. Advances in molecular genetic diagnostics have made it possible to identify new RMS subgroups within traditional morphological entities. One of these subgroups comprises rare tumors characterized by epithelioid and spindle cell morphology, a highly aggressive clinical course with pronounced tendency to intraosseous growth, and the presence of pathognomonic recurring genetic aberrations—chimeric genes/transcripts EWSR1::TFCP2, FUS::TFCP2, or MEIS1::NCOA2. Starting from 2018, only 26 reported cases of RMS have been assigned to this subgroup. The rarity of such tumors hampers their correct diagnostics for both anatomic pathologists and molecular oncologists. Here, we describe a clinical case of intraosseous spindle cell RMSs expressing the EWSR1::TFCP2 fusion gene, encountered for the first time in our practice, in a 16-yr-old female patient presenting with mandibular lesion. The diagnostic process took considerable time and involved RNA sequencing—a high-throughput method of molecular genetic research. The tumor was extremely aggressive, showing resistance to polychemotherapy, radiation therapy, and crizotinib-targeted therapy, with the fatal outcome.
- 29 June 2022
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 8 (5)
Open AccessCase report: EWSR1-TFCP2 in an adolescent represents an extremely rare and aggressive form of intraosseous spindle cell rhabdomyosarcomas
The World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone subdivides rhabdomyosarcomas (RMSs) into alveolar, embryonal, pleomorphic, and spindle cell RMSs. Advances in molecular genetic diagnostics have made it possible to identify new RMS subgroups within traditional morphological entities. One of these subgroups comprises rare tumors characterized by epithelioid and spindle cell morphology, a highly aggressive clinical course with pronounced tendency to intraosseous growth, and the presence of pathognomonic recurring genetic aberrations—chimeric genes/transcripts EWSR1::TFCP2, FUS::TFCP2, or MEIS1::NCOA2. Starting from 2018, only 26 reported cases of RMS have been assigned to this subgroup. The rarity of such tumors hampers their correct diagnostics for both anatomic pathologists and molecular oncologists. Here, we describe a clinical case of intraosseous spindle cell RMSs expressing the EWSR1::TFCP2 fusion gene, encountered for the first time in our practice, in a 16-yr-old female patient presenting with mandibular lesion. The diagnostic process took considerable time and involved RNA sequencing—a high-throughput method of molecular genetic research. The tumor was extremely aggressive, showing resistance to polychemotherapy, radiation therapy, and crizotinib-targeted therapy, with the fatal outcome.
- 17 June 2022
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 101 (3)
CONGENITAL NEUROBLASTOMA: A BIBLIOGRAPHICAL REVIEW AND OWN EXPERIENCE WRITE-UP OF THE NATIONAL SCIENTIFIC AND PRACTICAL CENTER FOR PEDIATRIC HEMATOLOGY, ONCOLOGY AND IMMUNOLOGY NAMED AFTER DMITRY ROGACHEV (MOSCOW, RUSSIA) ON PRENATAL DIAGNOSIS, CLINICAL COURSE AND TACTICS OF PATIENT TREATMENT
Congenital neuroblastoma (NB) accounts for 5 % of the total number of patients with this diagnosis and is characterized by a favorable remote prognosis. Most patients are stratified into a low-risk group and do not need chemotherapy. However, in some cases, at stage 4S the disease may develop life-threatening symptoms. Objective of the study: development of an algorithm for prenatal diagnosis and management of patients after birth with NB diagnosis. Materials and methods of research: the study includes 29 patients with a diagnosis of «neuroblastoma», first suspected during ultrasound of the fetus. Therapy and dynamic observation were carried out at the National Scientific and Practical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev (Moscow, Russia) from January 2012 to July 2021 (115 months). The stage of the disease was established in accordance with international criteria (G.M. Brodeur, 1993). Stratification for risk groups and therapy was carried out according to the recommendations of the modified protocol of the German group for the treatment of NB-2004. Results: the median of the gestation period at the time of detection of pathological changes in the fetus in 25 cases was 36 weeks (spread 28–40 weeks). In 4 patients, the exact period of detection of prenatal formation was not specified in medical documents. The most frequently detected pathology was interpreted as a voluminous formation of retroperitoneal space – 20/29 (70%) cases, in 7/29 (24%) – as the formation of the abdominal cavity and in 2/29 (6%) – as a chest formation. The delivery naturally was carried out in 17/29 (57.7%), in 12/29 (42.3%) a cesarean section was performed. Median age at diagnosis of «neuroblastoma» amounted to 1.9 months (spread 0.4–12.7 months). Lesions of the adrenal glands were the most commonly noted – 26/29 (89.7%), including bilateral – 8/26. Primary tumor was localized in the posterior mediastinum in 2 patients (6.9%), in one case retroperitoneally – (3.4%). No adverse cytogenetic markers were detected in any case. The first stage of the disease was established in 17/29 (58.6%) of patients, in one case, at the 2–4th stage, this stage was detected in 9/29 (31%) children. 28 (96.6%) out of 29 children were stratified into the observation group, one (3.4%) patient – into an intermediate risk group. In 3/29 (10.3%) of patients, the development of relapse/progression was noted. All patients are alive with median observation of 46.9 months (spread 3.5–99.6 months). Conclusion: Patients with intrauterine NB have favorable biological and cytogenetic characteristics of the tumor. The multidisciplinary approach in management of such patients from the moment of detection of fetal pathologies to the diagnosis of NB and following dynamic observation result in high survival rates.
- 17 June 2022
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 101 (3)
CONGENITAL NEUROBLASTOMA: A BIBLIOGRAPHICAL REVIEW AND OWN EXPERIENCE WRITE-UP OF THE NATIONAL SCIENTIFIC AND PRACTICAL CENTER FOR PEDIATRIC HEMATOLOGY, ONCOLOGY AND IMMUNOLOGY NAMED AFTER DMITRY ROGACHEV (MOSCOW, RUSSIA) ON PRENATAL DIAGNOSIS, CLINICAL COURSE AND TACTICS OF PATIENT TREATMENT
Congenital neuroblastoma (NB) accounts for 5 % of the total number of patients with this diagnosis and is characterized by a favorable remote prognosis. Most patients are stratified into a low-risk group and do not need chemotherapy. However, in some cases, at stage 4S the disease may develop life-threatening symptoms. Objective of the study: development of an algorithm for prenatal diagnosis and management of patients after birth with NB diagnosis. Materials and methods of research: the study includes 29 patients with a diagnosis of «neuroblastoma», first suspected during ultrasound of the fetus. Therapy and dynamic observation were carried out at the National Scientific and Practical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev (Moscow, Russia) from January 2012 to July 2021 (115 months). The stage of the disease was established in accordance with international criteria (G.M. Brodeur, 1993). Stratification for risk groups and therapy was carried out according to the recommendations of the modified protocol of the German group for the treatment of NB-2004. Results: the median of the gestation period at the time of detection of pathological changes in the fetus in 25 cases was 36 weeks (spread 28–40 weeks). In 4 patients, the exact period of detection of prenatal formation was not specified in medical documents. The most frequently detected pathology was interpreted as a voluminous formation of retroperitoneal space – 20/29 (70%) cases, in 7/29 (24%) – as the formation of the abdominal cavity and in 2/29 (6%) – as a chest formation. The delivery naturally was carried out in 17/29 (57.7%), in 12/29 (42.3%) a cesarean section was performed. Median age at diagnosis of «neuroblastoma» amounted to 1.9 months (spread 0.4–12.7 months). Lesions of the adrenal glands were the most commonly noted – 26/29 (89.7%), including bilateral – 8/26. Primary tumor was localized in the posterior mediastinum in 2 patients (6.9%), in one case retroperitoneally – (3.4%). No adverse cytogenetic markers were detected in any case. The first stage of the disease was established in 17/29 (58.6%) of patients, in one case, at the 2–4th stage, this stage was detected in 9/29 (31%) children. 28 (96.6%) out of 29 children were stratified into the observation group, one (3.4%) patient – into an intermediate risk group. In 3/29 (10.3%) of patients, the development of relapse/progression was noted. All patients are alive with median observation of 46.9 months (spread 3.5–99.6 months). Conclusion: Patients with intrauterine NB have favorable biological and cytogenetic characteristics of the tumor. The multidisciplinary approach in management of such patients from the moment of detection of fetal pathologies to the diagnosis of NB and following dynamic observation result in high survival rates.